Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Pathology

What Does PAS-Positive Diastase-Resistant Mean in GSD IV?

At a Glance

A "PAS-positive, diastase-resistant" biopsy finding means abnormal, unbranched clumps of glycogen have built up in your cells. This specific laboratory result is a classic hallmark used to diagnose Glycogen Storage Disease Type IV (GSD IV), usually followed by GBE1 genetic testing to confirm.

In this answer

3 sections

01

Breaking Down the Medical Jargon

02

Why Does This Happen in GSD IV?

03

What This Means for Your Body

When your biopsy report notes “PAS-positive, diastase-resistant inclusions,” it means the pathologist found clumps of abnormally structured glycogen in your tissue that cannot be easily broken down [1]. In Glycogen Storage Disease Type IV (GSD IV), a missing branching enzyme causes your body to build glycogen with long, unbranched chains [2]. Because these chains are shaped incorrectly, the standard enzyme used in the lab to dissolve normal glycogen (diastase) cannot digest them [3]. This specific laboratory finding from a liver or muscle biopsy is a classic hallmark used to help diagnose GSD IV [4].

Breaking Down the Medical Jargon

Pathologists use specific chemical tests to figure out exactly what is accumulating inside your cells. Here is what each part of that phrase means:

  • PAS-Positive: PAS stands for Periodic acid-Schiff. This is a special chemical dye that pathologists use to color sugars, carbohydrates, and glycogen bright pink or magenta under a microscope [5]. When a tissue sample is “PAS-positive,” it means it contains materials like glycogen that lit up when the dye was applied [6].
  • Diastase-Resistant: Diastase (also known as alpha-amylase) is an enzyme that acts like chemical scissors, specifically designed to cut up and digest normal glycogen [2][3]. To test if glycogen is normal, a pathologist will treat a tissue sample with diastase and then apply the PAS stain. If the glycogen is normal, the diastase destroys it, and the tissue will no longer stain pink. However, if the pink clumps remain brightly stained even after the diastase treatment, they are called diastase-resistant [6][7].
  • Inclusions: These are simply abnormal clumps, deposits, or masses of material trapped inside your cells [1][4].

Why Does This Happen in GSD IV?

To understand why your glycogen resists digestion, it helps to visualize how glycogen is normally built. Healthy glycogen looks like a highly branched tree, which keeps it dissolved in fluid and makes it easy for enzymes to break it down for rapid energy.

In GSD IV, your body lacks a crucial protein called the glycogen branching enzyme (GBE1) [8]. Without this enzyme, your cells build glycogen that has very long, straight chains with almost no branches [9][10].

Because of this abnormal shape, the glycogen molecules become stiff, resist dissolving in water, and tangle together into dense clumps known in pathology as polyglucosan bodies or “amylopectin-like” glycogen [9][11]. The laboratory enzyme diastase cannot easily grip or cut these tangled, unbranched chains, making them “diastase-resistant” [12][3][13].

What This Means for Your Body

Just as the diastase enzyme in the laboratory cannot break down these abnormal glycogen inclusions, your body’s natural enzymes struggle to break them down as well. Over time, these polyglucosan bodies accumulate in the cells of vital organs—most commonly the liver, skeletal muscles, and heart [14][8].

Because they cannot be cleared away, these clumps physically crowd the inside of the cells. This buildup can eventually lead to cellular damage and drive the primary symptoms of GSD IV, such as liver scarring (fibrosis) or muscle weakness [8][15].

While a biopsy showing these inclusions is a strong indicator of GSD IV, it is typically considered an initial step [16]. To formally confirm the diagnosis, your care team will likely order genetic testing to look for the specific mutation in the GBE1 gene [16][2]. Knowing this information helps your medical team understand exactly what is happening in your cells so they can carefully monitor your organs and work with you to manage your symptoms moving forward.

Common questions in this guide

What does PAS-positive mean on a biopsy report?
PAS stands for Periodic acid-Schiff, a special dye used to color glycogen bright pink under a microscope. A PAS-positive result means the tissue sample contains substances like glycogen that absorbed this chemical dye.
Why is the glycogen in GSD IV diastase-resistant?
In GSD IV, a missing enzyme causes the body to build abnormally long, unbranched chains of glycogen. The lab enzyme diastase is meant to cut up normal glycogen, but it cannot easily break down these tangled, unusually shaped chains, making them resistant to digestion.
What are polyglucosan bodies?
Polyglucosan bodies are dense clumps of abnormal, unbranched glycogen that tangle together. In GSD IV, these stiff inclusions build up inside the cells of vital organs like the liver, muscles, and heart because the body cannot naturally dissolve them.
Does this biopsy result confirm a GSD IV diagnosis?
While finding PAS-positive, diastase-resistant inclusions is a strong indicator of GSD IV, it is typically just an initial step. Your medical team will usually order genetic testing to look for mutations in the GBE1 gene to formally confirm the diagnosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my biopsy report specify how much of the tissue is affected by these inclusions?
  2. 2.Are these inclusions currently affecting my liver, my muscles, or my heart the most based on my other tests?
  3. 3.Will we be doing genetic testing to confirm the GBE1 mutation now that we have these biopsy results?
  4. 4.What is our specific plan for monitoring the health of the organs where these inclusions were found?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

How is GSD IV Different from GSD I and Pompe Disease?Does a Liver Transplant Cure Glycogen Storage Disease IV?Does Low GBE1 Enzyme Activity Cause Severe GSD IV?How Does Glycogen Storage Disease Type IV Affect the Heart?What Are the New Treatments for GSD IV and APBD?Is Glycogen Storage Disease Type IV Hereditary?Will My Child Outgrow Non-Progressive Hepatic GSD IV?How Does Uncooked Cornstarch Treat GSD Type IV?Why is APBD Misdiagnosed as MS or ALS? Key Differences

References

References (16)
  1. 1

    Case of Neonatal Fatality from Neuromuscular Variant of Glycogen Storage Disease Type IV.

    Sandhu T, Polan M, Yu Z, et al.

    JIMD reports 2019; (45()):51-55 doi:10.1007/8904_2018_142.

    PMID: 30311141
  2. 2

    Two cases of a non-progressive hepatic form of glycogen storage disease type IV with atypical liver pathology.

    Ichimoto K, Fujisawa T, Shimura M, et al.

    Molecular genetics and metabolism reports 2020; (24()):100601 doi:10.1016/j.ymgmr.2020.100601.

    PMID: 32455116
  3. 3

    Polyglucosan storage myopathies.

    Hedberg-Oldfors C, Oldfors A

    Molecular aspects of medicine 2015; (46()):85-100.

    PMID: 26278982
  4. 4

    Novel pathogenic variants in GBE1 causing fetal akinesia deformation sequence and severe neuromuscular form of glycogen storage disease type IV.

    Radhakrishnan P, Moirangthem A, Nayak SS, et al.

    Clinical dysmorphology 2019; (28(1)):17-21 doi:10.1097/MCD.0000000000000248.

    PMID: 30303820
  5. 5

    Succinylation-Alcian Blue Staining of Mucins on Polyvinylidene Difluoride Membranes.

    Kameyama A, Dong W, Matsuno YK

    Methods in molecular biology (Clifton, N.J.) 2015; (1314()):325-31 doi:10.1007/978-1-4939-2718-0_33.

    PMID: 26139280
  6. 6

    GYG1 gene mutations in a family with polyglucosan body myopathy.

    Fanin M, Torella A, Savarese M, et al.

    Neurology. Genetics 2015; (1(3)):e21 doi:10.1212/NXG.0000000000000021.

    PMID: 27066558
  7. 7

    Glycogen Storage Disease Type IV Diagnosed at Fetal Autopsy.

    Butler DC, Glen WB, Schandl C, Phillips A

    Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2020; (23(4)):301-305 doi:10.1177/1093526619890224.

    PMID: 31747834
  8. 8

    Liver Transplantation for Glycogen Storage Disease Type IV.

    Liu M, Sun LY

    Frontiers in pediatrics 2021; (9()):633822 doi:10.3389/fped.2021.633822.

    PMID: 33681109
  9. 9

    A Modified Enzymatic Method for Measurement of Glycogen Content in Glycogen Storage Disease Type IV.

    Yi H, Zhang Q, Yang C, et al.

    JIMD reports 2016; (30()):89-94 doi:10.1007/8904_2015_522.

    PMID: 27344645
  10. 10

    Update on polyglucosan storage diseases.

    Cenacchi G, Papa V, Costa R, et al.

    Virchows Archiv : an international journal of pathology 2019; (475(6)):671-686 doi:10.1007/s00428-019-02633-6.

    PMID: 31363843
  11. 11

    Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency.

    Thomsen C, Malfatti E, Jovanovic A, et al.

    Neuropathology and applied neurobiology 2022; (48(1)):e12761 doi:10.1111/nan.12761.

    PMID: 34405429
  12. 12

    Polyglucosan Bodies in Placental Extravillious Trophoblast for the Diagnosis of Fatal Perinatal Neuromuscular-type Glycogen Storage Disease Type IV.

    Yu W, Brundler MA, Wright JR

    Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2018; (21(4)):423-427 doi:10.1177/1093526617707852.

    PMID: 28497716
  13. 13

    Glycogenin-1 deficiency mimicking limb-girdle muscular dystrophy.

    Lefeuvre C, Schaeffer S, Carlier RY, et al.

    Molecular genetics and metabolism reports 2020; (24()):100597 doi:10.1016/j.ymgmr.2020.100597.

    PMID: 32477874
  14. 14

    Systemic Disease Progression and Neurodegeneration in the Gbe1ys/ys Mouse Model of Glycogen Storage Disease Type IV.

    Choi SJ, Koch RL, Gibson RA, et al.

    The American journal of pathology 2026; (196(3)):731-744 doi:10.1016/j.ajpath.2025.11.006.

    PMID: 41407198
  15. 15

    Biopsy-Proven Reversal of F4 Cirrhosis in Classic Hepatic Glycogen Storage Disease Type IV: A 42-Year Follow-Up Without Transplantation.

    Mino M, Mori N, Shimomura Y, et al.

    Hepatology research : the official journal of the Japan Society of Hepatology 2026; (56(4)):629-634 doi:10.1111/hepr.70084.

    PMID: 41428406
  16. 16

    Glycogen Storage Disease Type IV: A Case With Histopathologic Findings in First-Trimester Placental Tissue.

    Bendroth-Asmussen L, Aksglaede L, Gernow AB, Lund AM

    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2016; (35(1)):38-40 doi:10.1097/PGP.0000000000000214.

    PMID: 26166723

This page explains biopsy pathology terms for educational purposes only. Always consult your hepatologist, neurologist, or genetic counselor for help interpreting your specific GSD IV laboratory results.

Get notified when new evidence is published on Glycogen Storage Disease Type IV.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.